Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

73.050
-0.500-0.68%
Volume:2.62M
Turnover:191.18M
Market Cap:21.84B
PE:-38.25
High:74.800
Open:73.500
Low:71.000
Close:73.550
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.75
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.66
PE(LYR):-38.25
PS:22.37

Loading ...

KeyMed Bio-B Announces Departure of Non-Executive Director

Stock News
·
Sep 06

Keymed Biosciences Reports Resignation of Non-Executive Director Dr. Min Chuan Wang

Bulletin Express
·
Sep 06

Keymed Biosciences Files Board, Committee Member List with Disclosure Roles

Reuters
·
Sep 06

Keymed Biosciences Non-Executive Director Min Chuan Wang Resigns

Reuters
·
Sep 06

HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Stock News
·
Sep 03

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Reuters
·
Sep 03

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

MT Newswires
·
Sep 03

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

Reuters
·
Sep 02

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS
·
Sep 02

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS
·
Sep 02

KEYMED BIO-B: DFZQ Disposes of Shares, Long Position Falls to 4.98%

HK Disclosure
·
Sep 02

Keymed Bio-B Reports No Share Capital Changes for August 2026, Confirms Adequate Public Float

Bulletin Express
·
Sep 02

Fund Manager Trims Stake in KEYMED BIO-B With HK$3.76M Share Sale

Stock News
·
Sep 01

KEYMED BIO-B: 汇添富基金管理股份有限公司 Disposes, Long Position Falls to 4.98%

HK Disclosure
·
Sep 01

Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call

Deep News
·
Aug 23

Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call

Deep News
·
Aug 23

Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall St.
·
Aug 22

Citi Raises Keymed Bio's Target Price to HK$97.5, Maintains Buy/High-Risk Rating

Stock News
·
Aug 21

Movement Alert|KEYMED BIO-B Rises 5.14% in Regular Trading, Proposed STAR Market Listing and H1 Profit Turnaround Continue to Drive Gains

Market Focus
·
Aug 21

Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last

Simply Wall St.
·
Aug 21